Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in the Mozambican Population: A Cross-Sectional Serologic Study in 3 Cities, July-August 2020

被引:3
|
作者
Arnaldo, Paulo [1 ]
Mabunda, Nedio [1 ]
Young, Peter Wesley [2 ]
Tran, Tiffany [2 ]
Sitoe, Nadia [3 ]
Chelene, Imelda [3 ]
Nhanombe, Armando [4 ]
Ismael, Nalia [3 ]
Junior, Antonio [5 ]
Cubula, Basilio [6 ]
Inlamea, Osvaldo Frederico [4 ]
Gudo, Eduardo, Jr. [6 ,7 ]
Jani, Ilesh Vinodrai [6 ,7 ]
机构
[1] Inst Nacl Saude, Dept Regulacao & Promocao Invest Saude, Maputo, Mozambique
[2] US Ctr Dis Control & Prevent, Div Global HIV & TB, Maputo, Mozambique
[3] Inst Nacl Saude, Dept Plataformas Tecnol, Maputo, Mozambique
[4] Inst Nacl Saude, Dept Observacao Saude, Maputo, Mozambique
[5] Inst Nacl Saude, Dept Gestao & Coordenacao Invest Saude, Maputo, Mozambique
[6] Inst Nacl Estat, Dept Metodos, Maputo, Mozambique
[7] Inst Nacl Saude, Off Director, Maputo, Mozambique
基金
比尔及梅琳达.盖茨基金会;
关键词
seroprevalence; general population; higher-risk occupational groups; SARS-CoV-2; Mozambique; ANTI-SARS-COV-2 IGG ANTIBODIES; SEROPREVALENCE; HOUSEHOLD; INFECTIONS;
D O I
10.1093/cid/ciac516
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The extent of population exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was uncertain in many African countries during the onset of the pandemic. Methods We conducted a cross-sectional study and randomly selected and surveyed general population and occupational groups from 6 July to 24 August 2020, in 3 cities in Mozambique. Anti-SARS-CoV-2-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies were measured using a point-of-care rapid test. The prevalence was weighted for population (by age, sex, and city) and adjusted for test sensitivity and specificity. Results A total of 21 183 participants, including 11 143 from the general population and 10 040 from occupational groups, were included across all 3 cities. General population seropositivity (IgM or IgG) prevalence was 3.0% (95% confidence interval [CI], 1.0%-6.6%) in Pemba, 2.1% (95% CI, 1.2%-3.3%) in Maputo City, and 0.9% (95% CI, .1%-1.9%) in Quelimane. The prevalence in occupational groups ranged from 2.8% (95% CI, 1.3%-5.2%) to 5.9% (95% CI, 4.3%-8.0%) in Pemba, 0.3% (95% CI, .0%-2.2%) to 4.0% (95% CI, 2.6%-5.7%) in Maputo City, and 0.0% (95% CI, .0%-.7%) to 6.6% (95% CI, 3.8%-10.5%) in Quelimane, and showed variations between the groups tested. Conclusions In the first representative COVID-19 serosurveys in Mozambique, in mid-2020, weighted and assay-adjusted seroprevalence in 3 provincial capitals of anti-SARS-CoV-2 ranged from 0.9% to 3.0%, whereas adjusted prevalence in occupational groups ranged from 0.0% to 6.6% with variation between groups. Exposure to SARS-CoV-2 was extensive during the first pandemic wave, and transmission may have been more intense among occupational groups. These data have been of utmost importance to inform public health intervention to control and respond to the pandemic in Mozambique.
引用
收藏
页码:S285 / S293
页数:9
相关论文
共 50 条
  • [41] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Environmental Contamination and Childbirth
    Hermesch, Amy C.
    Horve, Patrick F.
    Edelman, Alison
    Dietz, Leslie
    Constant, David
    Fretz, Mark
    Messer, William B.
    Martindale, Robert
    Van den Wymelenberg, Kevin
    OBSTETRICS AND GYNECOLOGY, 2020, 136 (04): : 827 - 829
  • [42] Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Kabi, Arup K.
    Pal, Maynak
    Gujjarappa, Raghuram
    Malakar, Chandi C.
    Roy, Mithun
    JOURNAL OF HETEROCYCLIC CHEMISTRY, 2023, 60 (02) : 165 - 182
  • [43] Smoking and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
    Lee, Sang Chul
    Son, Kang Ju
    Kim, Dong Wook
    Han, Chang Hoon
    Choi, Yoon Jung
    Kim, Seong Woo
    Park, Seon Cheol
    NICOTINE & TOBACCO RESEARCH, 2021, 23 (10) : 1787 - 1792
  • [44] Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey
    Mulenga, Lloyd B.
    Hines, Jonas Z.
    Fwoloshi, Sombo
    Chirwa, Lameck
    Siwingwa, Mpanji
    Yingst, Samuel
    Wolkon, Adam
    Barradas, Danielle T.
    Favaloro, Jennifer
    Zulu, James E.
    Banda, Dabwitso
    Nikoi, Kotey, I
    Kampamba, Davies
    Banda, Ngawo
    Chilopa, Batista
    Hanunka, Brave
    Stevens, Thomas L., Jr.
    Shibemba, Aaron
    Mwale, Consity
    Sivile, Suilanji
    Zyambo, Khozya D.
    Makupe, Alex
    Kapina, Muzala
    Mweemba, Aggrey
    Sinyange, Nyambe
    Kapata, Nathan
    Zulu, Paul M.
    Chanda, Duncan
    Mupeta, Francis
    Chilufya, Chitalu
    Mukonka, Victor
    Agolory, Simon
    Malama, Kennedy
    LANCET GLOBAL HEALTH, 2021, 9 (06): : E773 - E781
  • [45] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020
    Hoover, Susan E.
    Reed, Valerie
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2022, 2 (01):
  • [46] Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
    Sidy Mohamed Seck
    Moustapha Mbow
    Yaya Kane
    Mouhamadou Moustapha Cisse
    Gnagna Faye
    Adama Kama
    Moussa Sarr
    Pamela Nitcheu
    Mohamed Dahaba
    Ibrahima Mbemba Diallo
    Mame Selly Diawara
    Lotingo Nehemie Motoula Latou
    Yacine Dia
    Souleymane Mboup
    BMC Nephrology, 22
  • [47] Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
    Seck, Sidy Mohamed
    Mbow, Moustapha
    Kane, Yaya
    Cisse, Mouhamadou Moustapha
    Faye, Gnagna
    Kama, Adama
    Sarr, Moussa
    Nitcheu, Pamela
    Dahaba, Mohamed
    Diallo, Ibrahima Mbemba
    Diawara, Mame Selly
    Latou, Lotingo Nehemie Motoula
    Dia, Yacine
    Mboup, Souleymane
    BMC NEPHROLOGY, 2021, 22 (01)
  • [48] Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom
    Vihta, Karina-Doris
    Pouwels, Koen B.
    Peto, Tim E. A.
    Pritchard, Emma
    Eyre, David W.
    House, Thomas
    Gethings, Owen
    Studley, Ruth
    Rourke, Emma
    Cook, Duncan
    Diamond, Ian
    Crook, Derrick
    Matthews, Philippa C.
    Stoesser, Nicole
    Walker, Ann Sarah
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E329 - E337
  • [49] Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
    Althoff, Keri N.
    Schlueter, David J.
    Anton-Culver, Hoda
    Cherry, James
    Denny, Joshua C.
    Thomsen, Isaac
    Karlson, Elizabeth W.
    Havers, Fiona P.
    Cicek, Mine S.
    Thibodeau, Stephen N.
    Pinto, Ligia A.
    Lowy, Douglas
    Malin, Bradley A.
    Ohno-Machado, Lucila
    Williams, Carolyn
    Goldstein, David
    Kouame, Aymone
    Ramirez, Andrea
    Roman, Adrienne
    Sharpless, Norman E.
    Gebo, Kelly A.
    Schully, Sheri D.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 584 - 590
  • [50] Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections: a nationwide population-based study
    Park, Seon Cheol
    Won, Sun Young
    Kim, Na Hye
    Choi, Heun
    Youk, Tae Mi
    Lee, Hyun Jung
    Jeon, Han Ho
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (03)